Skip to main content
. 2020 Dec 24;2(1):33–42. doi: 10.1016/j.xfss.2020.12.005

Figure 2.

Figure 2

ACE2 mRNA and protein expressions in human oocytes, embryos, and follicular cells. (A) RT-qPCR analysis of human ACE2 mRNA expression in GV- and MII-stage oocytes, BL (n = 3 pools of oocytes or embryos), CC, and GC (n = 3). Relative expression of ACE2 mRNA was normalized to GAPDH expression and presented as a bar graph. (B) Capillary Western blot of total ACE2 protein expression and (C) fold change in the abundance of ACE2 protein (100 kDa) and putative variants of 130 kDa (ACE2-V1), 62 kDa (ACE2-V2), and 53 kDa (ACE2-V3) in MII-stage oocytes, 1C- and BL-stage embryos, CC, and GC (n = 3 replicates). Arrow indicates the target protein. ACE2 protein expression was normalized to the total protein present in each sample, and data were presented as average protein fold change from 3 experiments. All bar graphs show the mean ± SEM. Different letters above the bars in graph represent the statistical difference (P < .05) determined by 1-way ANOVA followed by Tukey’s test. 1C = 1-cell; ACE2 = angiotensin 1-converting enzyme 2; ANOVA = analysis of variance; BL = blastocyst; CC = cumulus cells; GC = granulosa cells; GV = germinal vesicle; MII = metaphase II; mRNA = messenger ribonucleic acid; ND = nondetectable; RT-qPCR = quantitative reverse transcription polymerase chain reaction; SEM = standard error of the mean.